Élie Besserer-Offroy

Prix et distinctions

• (2020) Fellow [FACSc]. Association of Clinical Scientists.
• (2015) Member [MRSB]. Royal Society of Biology.

Financement

• Subvention. FOLOVAT, Développment de nouvelles sondes de radio-théranostique ciblant le récepteur au folate pour le traitement des cancers de l'ovaire. Cancéropole Nord-Ouest (Lille, France). Projets émergents. 20 000 EUR. (2025-2026).
• Subvention. CONCERTO, Collaborative Network for Cancer Radionuclide Therapy Development. Agence Nationale de la Recherche (Paris, France). Projets AMI CaeSAR. 296 000 EUR. (2025-2028).
  Numéro de subvention : ANR-23-EXES-001.
• Subvention. RECITAL. Université de Caen Normandie (Caen, France). Laboratoire partenaire international. 15 000 EUR. (2024-2026).
• Bourse. Innovations thérapeutiques ciblant le récepteur à l'apéline dans les cancers localement agressifs. Mitacs (Vancouver, Canada). Bourses de recherche Globalink. 12 000 $. (2024).
  Numéro de subvention : IT40001 .
• Subvention. THERANOVCA. Région Normandie (Caen, France). Chaire d'excellence en recherche. 850 000 EUR. (2023-2026).
• Subvention. An Accelerated Platform using Lead-212 Targeted α-particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboration. Prostate Cancer Foundation (Santa Monica, États-Unis). TACTICAL Award. 10 000 000 USD. (2023-2026).
  Numéro de subvention : 22TACT01.
• Subvention. Fibroblast Activation Protein (FAP) as a New Theranostic Target for Brain Tumor. UCLA SPORE in Brain Cancer (Los Angeles, États-Unis). 50 000 USD. (2022-2023).
• Subvention. The UCLA Neurotheranostics Program. UCLA Jonsson Comprehensive Cancer Center (Los Angeles, États-Unis). UCLA CTSI-DGSOM Seed Grant. 250 000 USD. (2021-2023).
• Subvention. Investigating the role of APJ heterodimers in pain modulation. Canadian Institutes of Health Research (Ottawa, Canada). 38 333 $. (2019-2022).
  Numéro de subvention : N/A. Voir plus
• Subvention. Comprendre le rôle des hétérodimères du récepteur à l'apéline dans la modulation de la douleur. Fonds de Recherche du Québec - Santé (Montreal, Canada). 90 000 $. (2018-2020).
  Numéro de subvention : 255989. Voir plus
• Subvention. Elucidation of the functional role of APJ/KOR heterodimers in the modulation of pain. Sherbrooke Neuroscience Centre (Sherbrooke, Canada). Pilot Study Project Grant. 12 500 $. (2018-2019).
• Subvention. NTS1 modulation by allosteric lipopeptides. Fonds de recherche du Québec - Nature et Technologies (Québec, Canada). Team Research Grant. 162 000 $. (2017-2020).
  Numéro de subvention : 2018-PR-207951.
• Subvention. Understanding the NTS1 receptor signaling with new lipopeptide allosteric modulators. Sherbrooke Neuroscience Centre (Sherbrooke, Canada). Pilot Study Project Grant. 7 500 $. (2016-2017).

Publications

Articles

• Marie-Edith Nepveu-Traversy, Malihe Hassanzadeh, Laurent Bruneau-Cossette, Élie Besserer-Offroy, Rebecca Brouillette, Sandra Morissette, Hassan Traboulsi, Karyn Kirby, Alexandre Murza, Jean-Michel Longpré, Billy Breton, Fernand-Pierre Gendron, Simon Gaudreau, Pierre-Luc Boudreault, Philippe Sarret. (2025). Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors. Nature Communications. DOI
• Émile Breault, Rebecca L. Brouillette, Terence E. Hébert, Philippe Sarret, Élie Besserer-Offroy. (2025). Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail. CNS Drugs. DOI
• Brouillette, R.L., Mona, C.E., Desgagné, M., Hassanzedeh, M., Breault, É., Lussier, F., Belleville, K., Longpré, J.-M., Grandbois, M., Boudreault, P.-L., Besserer-Offroy, É., Sarret, P. (2025). A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new β-arrestin inhibitor. Pharmacological Research. DOI
• Midavaine, É., Brouillette, R.L., Théberge, E., Mona, C.E., Kashem, S.W., Côté, J., Zeugin, V., Besserer-Offroy, É., Longpré, J.-M., Marsault, É., Sarret, P. (2024). Discovery of a CCR2-targeting pepducin therapy for chronic pain. Pharmacological Research. DOI
• Taddio, M.F., Doshi, S., Masri, M., Jeanjean, P., Hikmat, F., Gerlach, A., Nyiranshuti, L., Rosser, E.W., Schaue, D., Besserer-Offroy, E., Carlucci, G., Radu, C.G., Czernin, J., Lückerath, K., Mona, C.E. (2024). Evaluating [²²⁵Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging. DOI
• Pétigny, C., Dumont, A.-A., Giguère, H., Iftinca, M., Altier, C., Besserer-Offroy, É., Leduc, R., Collette, A., Holleran, B.J., Auger-Messier, M. (2022). Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation. International Journal of Molecular Sciences. DOI
• Tran, K., Sainsily, X., Côté, J., Coquerel, D., Couvineau, P., Saibi, S., Haroune, L., Besserer-Offroy, E., Flynn-Robitaille, J., Resua Rojas, M., Murza, A., Longpré, J.-M., Auger-Messier, M., Lesur, O., Bouvier, M., Marsault, E., Boudreault, P.-L., Sarret, P. (2022). Size-Reduced Macrocyclic Analogues of [Pyr¹]-apelin-13 Showing Negative Gα₁₂Bias Still Produce Prolonged Cardiac Effects. Journal of Medicinal Chemistry. DOI
• Vivancos, M., Fanelli, R., Besserer-Offroy, É., Beaulieu, S., Chartier, M., Resua-Rojas, M., Mona, C.E., Previti, S., Rémond, E., Longpré, J.-M., Cavelier, F., Sarret, P. (2021). Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Behavioural Brain Research. DOI
• Michaelian, N., Sadybekov, A., Besserer-Offroy, É., Han, G.W., Krishnamurthy, H., Zamlynny, B.A., Fradera, X., Siliphaivanh, P., Presland, J., Spencer, K.B., Soisson, S.M., Popov, P., Sarret, P., Katritch, V., Cherezov, V. (2021). Structural insights on ligand recognition at the human leukotriene B4 receptor 1. Nature Communications. DOI
• Besserer-Offroy, É., Brouillette, R.L., Longpré, J.-M., Sarret, P. (2020). Assessing Gαq/15-signaling with IP-One: Single Plate Transfection and Assay Protocol for Cell-Based High-Throughput Assay. Bio-protocol. DOI
• Brouillette, R.L., Besserer-Offroy, É., Mona, C.E., Chartier, M., Lavenus, S., Sousbie, M., Belleville, K., Longpré, J.-M., Marsault, É., Grandbois, M., Sarret, P. (2020). Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain. Pharmacological Research. DOI
• Besserer-Offroy, É., Tétreault, P., Brouillette, R.L., René, A., Murza, A., Fanelli, R., Kirby, K., Parent, A., Dubuc, I., Beaudet, N., Côté, J., Longpré, J.-M., Martinez, J., Cavelier, F., Sarret, P. (2020). Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8–13) analog. Data in Brief. DOI
• Tétreault, P., Besserer-Offroy, É., Brouillette, R.L., René, A., Murza, A., Fanelli, R., Kirby, K., Parent, A.J., Dubuc, I., Beaudet, N., Côté, J., Longpré, J.-M., Martinez, J., Cavelier, F., Sarret, P. (2020). Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. European Journal of Pharmacology. DOI
• Sadybekov, A.A., Brouillette, R.L., Marin, E., Sadybekov, A.V., Luginina, A., Gusach, A., Mishin, A., Besserer-Offroy, É., Longpré, J.-M., Borshchevskiy, V., Cherezov, V., Sarret, P., Katritch, V. (2020). Structure-based virtual screening of ultra-large library yields potent antagonists for a lipid gpcr. Biomolecules. DOI
• Boulkeroua, C., Ayari, H., Khalfaoui, T., Lafrance, M., Besserer-Offroy, É., Ekindi, N., Sabbagh, R., Dumaine, R., Lesur, O., Sarret, P., Chraibi, A. (2019). Apelin-13 regulates vasopressin-induced aquaporin-2 expression and trafficking in kidney collecting duct cells. Cellular Physiology and Biochemistry. DOI
• Besserer-Offroy, E., Sarret, P. (2019). Sending out biased signals: An appropriate proposition for pain?. Douleur et Analgesie. DOI
• Gusach, A., Luginina, A., Marin, E., Brouillette, R.L., Besserer-Offroy, É., Longpré, J.-M., Ishchenko, A., Popov, P., Patel, N., Fujimoto, T., Maruyama, T., Stauch, B., Ergasheva, M., Romanovskaia, D., Stepko, A., Kovalev, K., Shevtsov, M., Gordeliy, V., Han, G.W., ... Cherezov, V. (2019). Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors. Nature Communications. DOI
• Luginina, A., Gusach, A., Marin, E., Mishin, A., Brouillette, R., Popov, P., Shiriaeva, A., Besserer-Offroy, É., Longpré, J.-M., Lyapina, E., Ishchenko, A., Patel, N., Polovinkin, V., Safronova, N., Bogorodskiy, A., Edelweiss, E., Hu, H., Weierstall, U., Liu, W., ... Cherezov, V. (2019). Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. Science Advances. DOI
• St-Pierre, D., Cabana, J., Holleran, B.J., Besserer-Offroy, É., Escher, E., Guillemette, G., Lavigne, P., Leduc, R. (2018). Angiotensin II cyclic analogs as tools to investigate AT ₁ R biased signaling mechanisms. Biochemical Pharmacology. DOI
• Sousbie, M., Besserer-Offroy, E., Brouillette, R.L., Longpré, J.-M., Leduc, R., Sarret, P., Marsault, E. (2018). In Search of the Optimal Macrocyclization Site for Neurotensin. ACS Medicinal Chemistry Letters. DOI
• Lavenus, S., Simard, É., Besserer-Offroy, É., Froehlich, U., Leduc, R., Grandbois, M. (2018). Label-free cell signaling pathway deconvolution of angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIIIIV responses. Pharmacological Research. DOI
• Sousbie, M., Vivancos, M., Brouillette, R.L., Besserer-Offroy, É., Longpré, J.-M., Leduc, R., Sarret, P., Marsault, É. (2018). Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13). Journal of Medicinal Chemistry. DOI
• Besserer-Offroy, É., Bérubé, P., Côté, J., Murza, A., Longpré, J.-M., Dumaine, R., Lesur, O., Auger-Messier, M., Leduc, R., Marsault, É., Sarret, P. (2018). The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment. Pharmacological Research. DOI
• Murza, A., Sainsily, X., Côté, J., Bruneau-Cossette, L., Besserer-Offroy, Élie., Longpré, J.-M., Leduc, R., Dumaine, R., Lesur, O., Auger-Messier, M., Sarret, P., Marsault, É. (2017). Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. Organic and Biomolecular Chemistry. DOI
• Besserer-Offroy, É., Brouillette, R.L., Lavenus, S., Froehlich, U., Brumwell, A., Murza, A., Longpré, J.-M., Marsault, É., Grandbois, M., Sarret, P., Leduc, R. (2017). The signaling signature of the neurotensin type 1 receptor with endogenous ligands. European Journal of Pharmacology. DOI
• Fanelli, R., Floquet, N., Besserer-Offroy, E., Delort, B., Vivancos, M., Longpré, J.-M., Renault, P., Martinez, J., Sarret, P., Cavelier, F. (2017). Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues. Journal of Medicinal Chemistry. DOI
• Mona, C.E., Besserer-Offroy, É., Cabana, J., Leduc, R., Lavigne, P., Heveker, N., Marsault, É., Escher, E. (2016). Design, synthesis, and biological evaluation of CXCR4 ligands. Organic and Biomolecular Chemistry. DOI
• Murza, A., Sainsily, X., Coquerel, D., Côté, J., Marx, P., Besserer-Offroy, E., Longpré, J.-M., Lainé, J., Reversade, B., Salvail, D., Leduc, R., Dumaine, R., Lesur, O., Auger-Messier, M., Sarret, P., Marsault, E. (2016). Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions. Journal of Medicinal Chemistry. DOI
• Thomas, J.B., Vivancos, M., Giddings, A.M., Wiethe, R.W., Warner, K.R., Murza, A., Besserer-Offroy, E., Longpré, J.-M., Runyon, S.P., Decker, A.M., Gilmour, B.P., Sarret, P. (2016). Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2. ACS Chemical Neuroscience. DOI
• Hapəu, D., Rémond, E., Fanelli, R., Vivancos, M., René, A., Côté, J., Besserer-Offroy, É., Longpré, J.-M., Martinez, J., Zaharia, V., Sarret, P., Cavelier, F. (2016). Stereoselective Synthesis of β-(5-Arylthiazolyl) α-Amino Acids and Use in Neurotensin Analogues. European Journal of Organic Chemistry. DOI
• Mona, C.E., Besserer-Offroy, É., Cabana, J., Lefrançois, M., Boulais, P.E., Lefebvre, M.-R., Leduc, R., Lavigne, P., Heveker, N., Marsault, É., Escher, E. (2016). Structure-activity relationship and signaling of new chimeric CXCR4 agonists. Journal of Medicinal Chemistry. DOI
• Murza, A., Besserer-Offroy, E., Côté, J., Bérubé, P., Longpré, J.-M., Dumaine, R., Lesur, O., Auger-Messier, M., Leduc, R., Sarret, P., Marsault, E. (2015). C-terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action. Journal of Medicinal Chemistry. DOI
• Fanelli, R., Besserer-Offroy, E., René, A., Côté, J., Tétreault, P., Collerette-Tremblay, J., Longpré, J.-M., Leduc, R., Martinez, J., Sarret, P., Cavelier, F. (2015). Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues. Journal of Medicinal Chemistry. DOI
• Demeule, M., Beaudet, N., Régina, A., Besserer-Offroy, E., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., Béliveau, R., Longpré, J.-M., Marsault, E., Leduc, R., Lachowicz, J.E., Gonias, S.L., Castaigne, J.-P., Sarret, P. (2014). Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. Journal of Clinical Investigation. DOI
• Murza, A., Parent, A., Besserer-Offroy, E., Tremblay, H., Karadereye, F., Beaudet, N., Leduc, R., Sarret, P., Marsault, E. (2012). Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability. ChemMedChem. DOI

Autres contributions

Présentations

• Elie Besserer-Offroy. (2016). Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions. 46th annual meeting of the Society for Neuroscience. États-Unis.
• Elie Besserer-Offroy. (2016). β-arrestin-2-biased apelin receptor agonists as novel potent analgesics. Symposium de l'axe inflammation-douleur. Canada.
• Elie Besserer-Offroy. (2015). New biased analogs of Apelin-13 and their impacts on cardiovascular effects. 5è rencontre Montpellier-Sherbrooke. Canada.
• Elie Besserer-Offroy. (2013). Molecular Signature of the Neurotensin Receptor 1. 3è journée scientifique du Réseau québécois de recherche sur le médicament. Canada.
• Elie Besserer-Offroy. (2012). BRET-Based Assay Development for the Discovery of Novel GPCR Ligands. Institut de pharmacologie de Sherbrooke. Canada.
• Elie Besserer-Offroy. (2012). BRET-Based Assay Development for the Discovery of Novel GPCR Ligands. Journée Phare. Canada.

Activités professionnelles

• Inserm. Formateur Parcours-EDA. Paris, Île-de-France, France. (2024-).
• Poste d'invité. Université de Sherbrooke. Département de pharmacologie-physiologie. Professeur invité [Visiting Professor]. Sherbrooke, Quebec, Canada. (2023).
• Journal of Nuclear Medicine. Editorial Borad Member. (2022-).
• eLife Sciences Publications Ltd. eLife Ambassador. Cambridge, Cambridgeshire, Royaume-Uni. (2018-2019).